BNT164b1 not checked

BioNTech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection”In the company’s words, NCT05547464 on ClinicalTrials.gov
Tested for
Tuberculosis
Main trialPhase 1/2
“This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. This study includes: Part A (Phase Ib) and Part B (Phase IIa).”In the company’s words, NCT05547464 on ClinicalTrials.gov

Other drugs for Tuberculosis

All 15 drugs for Tuberculosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 12 Mar 2026 Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
Phase 1Completed 6 Jun 2025 Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BNT164b1

Following is part of Solo: you see every change to BNT164b1 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in